human
immunodefici
viru
type
caus
agent
aid
human
one
catastroph
pandem
affect
human
health
care
latter
th
centuri
best
hope
control
pandem
develop
success
prophylact
vaccin
howev
date
goal
proven
except
elus
recent
failur
experiment
aid
vaccin
phase
iib
studi
name
step
trial
intend
sole
elicit
cell
mediat
immun
respons
highlight
need
balanc
immun
respons
consist
cellular
immun
also
broad
potent
antibodi
respons
prevent
infect
articl
review
effort
made
point
elicit
antibodi
respons
especi
regard
use
dna
primeprotein
boost
regimen
proven
highli
effect
platform
induct
neutral
antibodi
anim
earli
phase
human
studi
sinc
discoveri
earli
implic
death
million
individu
estim
million
peopl
current
harbor
activ
infect
mani
even
without
knowledg
later
develop
acquir
immunodefici
syndrom
aid
estim
million
peopl
infect
alon
spread
show
littl
sign
slow
best
hope
control
pandem
effect
prophylact
vaccin
gener
believ
develop
effect
humor
cellular
immun
requir
provid
protect
infect
never
clear
roadmap
achiev
goal
last
two
decad
great
deal
inform
knowledg
accumul
regard
properti
variou
immun
respons
observ
infect
studi
prophylact
vaccin
develop
unfortun
sever
late
phase
clinic
trial
vaccin
candid
fail
provid
efficaci
time
also
wit
enorm
progress
induct
humor
cellular
immun
result
novel
strategi
antigen
design
vaccin
approach
allow
us
investig
potenti
protect
mechan
develop
effect
vaccin
prevent
infect
recent
phase
iib
trial
step
trial
novel
attempt
deliv
antigen
use
nonrepl
adenovir
vector
intend
prevent
diseas
induct
potent
cellular
immun
respons
peopl
still
debat
whether
inadequ
level
cellular
immun
may
respons
failur
candid
vaccin
outcom
highlight
need
balanc
immun
respons
consist
cellular
immun
also
inclus
broad
potent
neutral
antibodi
respons
recent
year
focu
hiv
vaccin
field
larg
induct
strong
cell
mediat
immun
respons
viru
especi
true
larg
effort
put
forth
induc
strong
cytotox
lymphocyt
ctl
respons
direct
viru
focu
induct
ctl
respons
driven
number
discoveri
implic
cell
vital
import
prevent
control
viral
infect
earli
work
role
ctl
respons
viral
infect
determin
induct
ctl
primari
correl
control
viremia
earli
infect
find
corrobor
discoveri
cell
absolut
requir
control
siv
infect
addit
evid
human
patient
capabl
control
viral
replic
without
therapi
call
elit
control
support
notion
strong
effect
ctl
respons
correl
virem
control
individu
theori
behind
design
cell
vaccin
presenc
strong
immedi
ctl
respons
present
time
viral
exposur
would
minimum
reduc
viral
load
infect
individu
reduc
acut
viremia
theori
support
data
indic
strong
ctl
respons
shown
capabl
protect
viral
infect
shiv
protect
model
success
rais
strong
cell
respons
protect
seen
shiv
challeng
model
cell
vaccin
appear
attract
platform
vaccin
develop
howev
despit
success
rais
strong
cell
respons
protect
capabl
vaccin
face
shiv
challeng
effect
vaccin
highli
pathogen
viral
challeng
much
less
substanti
furthermor
entir
cell
vaccin
theori
built
postinfect
protect
model
consid
induct
steril
immun
imposs
mission
therefor
unfortun
entir
surpris
cellbas
vaccin
shown
step
trial
despit
well
toler
immunogen
human
ultim
prove
ineffect
best
case
possibl
detriment
worst
continu
effort
improv
magnitud
breadth
cell
respons
futur
vaccin
develop
renew
focu
induct
function
antibodi
respons
mean
provid
earli
even
possibl
steril
immun
respons
induct
strong
function
antibodi
respons
form
broadli
neutral
antibodi
nab
current
one
sought
goal
field
vaccin
develop
unfortun
contain
array
protect
mechan
make
elicit
broad
potent
neutral
antibodi
respons
except
difficult
task
much
difficulti
rais
function
antibodi
respons
attribut
high
degre
divers
found
envelop
env
glycoprotein
major
target
neutral
antibodi
nab
viru
addit
difficulti
overcom
high
level
sequenc
divers
function
nab
must
also
abl
overcom
seri
intrins
defens
present
env
includ
high
level
glycosyl
epitop
mask
variabl
loop
cryptic
bind
domain
high
degre
entropi
present
env
protein
mask
function
import
domain
quaternari
interact
result
trimer
env
complex
addit
hiv
retroviru
integr
host
cell
genom
exist
narrow
window
neutral
antibodi
act
establish
infect
despit
protect
mechan
viru
util
number
monoclon
antibodi
mab
identifi
capabl
neutral
rel
wide
number
primari
isol
date
mean
provid
steril
immun
passiv
transfus
mab
shortli
viral
challeng
rel
high
level
antibodi
requir
prevent
infect
success
studi
demonstr
steril
immun
base
antibodi
mediat
mechan
inde
feasibl
signific
amount
work
invest
rais
high
qualiti
function
antibodi
respons
target
viru
much
work
focus
two
area
modul
vaccin
antigen
immun
regimen
use
deliv
antigen
earli
attempt
rais
antibodi
respons
viru
primarili
use
envelop
glycoprotein
env
cell
line
adapt
tcla
virus
realiz
signific
differ
antigen
envelop
deriv
tcla
primari
isol
one
first
studi
util
tcla
isol
iiib
chimpanze
challeng
model
studi
protect
effect
subunit
base
immun
studi
chimpanze
receiv
three
immun
transmembran
cytoplasm
tail
truncat
formul
aluminum
hydroxid
alum
base
upon
presenc
homolog
neutral
antibodi
respons
exceed
immun
anim
challeng
homolog
isol
iiib
administ
immun
chimpanze
studi
remain
free
viral
infect
six
month
challeng
appar
success
studi
other
led
test
tcla
base
recombin
protein
human
clinic
trial
mani
trial
base
immun
subunit
env
deriv
tcla
isol
iiib
mn
prove
safe
immunogen
trial
often
succeed
rais
bind
neutral
antibodi
respons
tcla
virus
similar
seen
protect
chimpanze
base
upon
inform
two
phase
iii
efficaci
trial
conduct
one
north
america
netherland
second
thailand
north
american
netherland
locat
individu
enrol
receiv
bival
vaccin
consist
two
clade
b
deriv
isol
mn
adjuv
alum
vaccine
studi
gener
posit
bind
antibodi
homolog
env
mani
gener
homolog
neutral
antibodi
respons
vaccin
strain
mn
despit
observ
reduct
rate
infect
placebo
vaccin
group
indic
vaccin
efficaci
similar
result
also
observ
thailand
locat
trial
thailand
arm
studi
enrol
intraven
drug
user
differ
north
american
counterpart
chosen
antigen
attempt
better
repres
circul
viru
thailand
locat
bival
formul
consist
clade
b
mn
clade
e
deriv
chosen
bind
antibodi
mn
neutral
antibodi
gener
result
immun
differ
rate
infect
exist
placebo
vaccin
arm
trial
failur
trial
actual
predict
vitro
neutral
assay
perform
start
two
trial
alreadi
demonstr
antibodi
elicit
tcla
env
antigen
mn
abl
neutral
primari
isol
failur
vaccin
trial
may
part
due
select
antigen
specif
deriv
tcla
isol
chosen
formul
howev
still
remain
seen
whether
select
antigen
better
repres
circul
popul
may
provid
protect
respons
viral
challeng
proven
abil
nab
provid
steril
immun
non
human
primat
challeng
model
enorm
amount
effort
put
design
immunogen
capabl
elicit
function
neutral
antibodi
respons
tabl
effort
focus
number
differ
techniqu
includ
limit
manipul
envelop
sequenc
make
structur
modif
envelop
increas
immunogen
potenti
import
poorli
immunogen
epitop
one
highli
critic
element
two
fail
phase
iii
trial
antigen
select
use
vaccin
particular
inclus
tcla
deriv
envelop
mn
mn
isol
repres
major
isol
seen
circul
global
popul
littl
surpris
particular
isol
use
immunogen
elicit
broadli
cross
reactiv
immun
respons
effort
design
immunogen
repres
isol
like
observ
vivo
set
use
consensu
central
envelop
sequenc
garner
attent
recent
year
one
studi
gener
artifici
envelop
antigen
base
constant
region
loop
group
consensu
sequenc
form
consensu
protein
investig
immunogen
guinea
pig
model
five
immun
either
protein
administ
ribicw
adjuv
result
sera
capabl
neutral
sensit
isol
high
titer
addit
posit
neutral
antibodi
difficult
neutral
isol
also
gener
peptid
adsorpt
perform
attempt
identifi
specif
neutral
antibodi
elicit
construct
demonstr
sensit
isol
primarili
neutral
antibodi
loop
unknown
ab
specif
elicit
larg
respons
neutral
resist
primari
isol
base
upon
first
consensu
immunogen
abil
rais
function
limit
antibodi
respons
second
gener
group
consensu
envelop
also
test
oppos
first
gener
construct
envelop
encod
consensu
sequenc
entir
envelop
oppos
primarili
constant
region
modif
variabl
loop
envelop
made
result
interpret
consensu
sequenc
author
modif
result
variabl
loop
slightli
shorter
averag
wild
type
envelop
protein
differ
construct
consensu
gene
administ
ribi
adjuv
success
broaden
neutral
antibodi
respons
compar
immun
wild
type
sequenc
deriv
primari
isol
jrfl
clade
b
clade
clade
c
howev
overal
breadth
still
limit
sera
still
unabl
neutral
major
prototyp
hiv
isol
serum
test
neutral
specif
larg
proport
neutral
activ
could
adsorb
peptid
loop
may
access
larg
fraction
primari
isol
larg
percentag
direct
antibodi
potenti
explain
limit
breadth
neutral
observ
immun
antigen
attempt
focu
antibodi
respons
singl
subtyp
subtyp
c
ancestr
consensu
gene
also
gener
immunogen
administ
three
dna
immun
guinea
pig
result
sera
capabl
recogn
greater
breadth
contemporari
clade
c
antigen
sera
gener
immun
wild
type
clade
c
immunogen
despit
increas
breadth
cross
reactiv
howev
littl
homolog
heterolog
neutral
observ
one
immun
anim
gener
antibodi
capabl
neutral
homolog
isol
none
anim
gener
antibodi
capabl
neutral
heterolog
primari
isol
similar
studi
also
complet
subtyp
b
ancestr
consensu
immunogen
use
subtyp
b
consensu
immunogen
evalu
guinea
pig
three
dna
immun
encod
differ
form
consensu
b
envelop
gene
elicit
humor
respons
compar
guinea
pig
immun
wildtyp
isol
studi
consensu
b
immunogen
elicit
neutral
antibodi
isol
rang
sensit
includ
subset
virus
repres
found
acut
infect
socal
tier
virus
phenomenon
observ
immun
wild
type
immunogen
base
upon
success
neutral
number
isol
author
continu
attempt
identifi
mechan
neutral
observ
viru
either
preexpos
contain
graft
mper
region
use
mean
identifi
presenc
coreceptor
mper
target
neutral
antibodi
howev
none
immun
anim
gener
antibodi
specif
gener
central
immunogen
among
larg
group
viral
isol
one
approach
enhanc
immunogen
hiv
construct
other
strategi
focus
structur
modif
exist
env
antigen
well
establish
variabl
loop
protect
function
import
domain
theoret
delet
variabl
loop
expos
function
import
domain
allow
antibodi
elicit
previous
obscur
region
oper
theori
number
studi
modifi
wild
type
envelop
delet
variabl
loop
one
first
studi
investig
role
variabl
loop
delet
alter
immunogen
parent
envelop
evalu
effect
delet
immunogen
sever
form
envelop
studi
evalu
wild
type
variabl
loop
delet
form
immunogen
deliv
dna
immun
abil
rais
bind
neutral
antibodi
rabbit
result
studi
indic
variabl
loop
delet
construct
increas
amount
bind
antibodi
elicit
subunit
envelop
despit
increas
bind
titer
howev
immun
wild
type
subunit
still
effect
elicit
bind
antibodi
neutral
sensit
isol
iiib
also
evalu
studi
immun
strictli
wild
type
elicit
highest
neutral
antibodi
titer
isol
elimin
variabl
loop
construct
detriment
effect
howev
elimin
observ
neutral
activ
like
due
extrem
sensit
isol
variabl
loop
mediat
neutral
addit
although
variabl
loop
delet
increas
bind
titer
immun
anim
still
manag
neutral
iiib
isol
case
anoth
studi
look
effect
elimin
loop
abil
rais
humor
immun
respons
studi
rabbit
given
dna
immun
encod
full
length
immunogen
one
partial
delet
loop
rais
antibodi
respons
test
neutral
breadth
potenc
panel
homolog
heterolog
isol
test
homolog
isol
potent
neutral
sera
rais
immun
delet
construct
addit
neutral
also
seen
frequent
higher
titer
six
heterolog
clade
b
isol
pattern
also
observ
rhesu
macaqu
immun
construct
follow
protein
boost
homolog
delet
broad
potent
neutral
antibodi
respons
rais
delet
construct
use
immunogen
compar
wild
type
immunogen
studi
delet
character
chang
antibodi
specif
elicit
compar
immun
wild
type
envelop
interestingli
immun
delet
construct
result
increas
target
loop
well
modul
ratio
serum
antibodi
capabl
outcompet
bind
util
delet
subtyp
c
immunogen
also
evalu
use
viral
envelop
model
subtyp
c
immunogen
comparison
immunogen
unmodifi
delet
immunogen
made
similar
result
seen
immunogen
increas
potenc
homolog
neutral
observ
delet
construct
use
addit
increas
albeit
limit
one
breadth
neutral
heterolog
clade
b
c
virus
also
observ
use
delet
character
humor
respons
rais
wild
type
variabl
loop
delet
construct
also
perform
comparison
humor
respons
seen
chronic
shiv
infect
macaqu
heterolog
hiv
infect
human
interestingli
quantiti
qualiti
specif
antibodi
respons
differ
greatli
group
immun
anim
subunit
immunogen
appear
immunogen
subunit
trend
observ
shiv
infect
macaqu
hiv
infect
human
equal
immunogen
addit
overal
bind
titer
also
significantli
lower
immun
anim
compar
infect
one
anoth
signific
differ
immun
infect
anim
involv
neutral
specif
serum
variabl
loop
modifi
construct
capabl
neutral
homolog
viru
discov
larg
due
recognit
loop
phenomenon
observ
infect
anim
area
access
hiv
virus
highli
polymorph
potenti
explain
limit
neutral
breadth
observ
immun
drastic
modif
hiv
envelop
also
made
remov
loop
alon
combin
background
also
investig
immun
construct
result
high
bind
titer
recombin
best
nab
titer
result
immun
wild
type
env
protein
immun
delet
construct
elicit
antibodi
respons
littl
neutral
activ
epitop
map
analysi
reveal
expectedli
delet
variabl
loop
shift
target
elicit
antibodi
howev
oftentim
shift
recognit
area
expos
surfac
protein
result
like
simpl
delet
variabl
loop
provid
necessari
increas
potenc
breadth
neutral
effect
combat
infect
immun
variabl
loop
delet
result
increas
qualiti
antibodi
respons
less
drastic
alter
viral
envelop
also
evalu
effect
immunogen
one
modif
alter
glycosyl
pattern
surfac
env
surfac
env
highli
glycosyl
carbohydr
encompass
total
molecular
weight
protein
well
document
chang
glycosyl
pattern
envelop
protein
signific
effect
antigen
envelop
neutral
sensit
parent
viru
chang
glycosyl
pattern
envelop
drastic
effect
phenotyp
may
also
possibl
alter
glycosyl
pattern
could
use
modul
immunogen
protein
one
potenti
use
chang
glycosyl
pattern
envelop
dampen
immun
respons
undesir
epitop
rel
difficult
rais
antibodi
sugar
right
identifi
self
immun
system
addit
glycan
unwant
area
effect
focus
humor
respons
desir
area
envelop
effort
made
extent
attempt
focu
antibodi
bind
site
studi
addit
seven
extra
glycan
elimin
bind
undesir
nonneutr
antibodi
preserv
bind
site
broadli
neutral
bind
site
antibodi
use
immunogen
rabbit
howev
end
mix
result
rabbit
immun
construct
ribi
adjuv
gener
posit
bind
antibodi
wild
type
env
protein
rais
highli
limit
neutral
antibodi
respons
analysi
immun
serum
also
reveal
limit
amount
antibodi
specif
similar
mab
antibodi
specif
construct
intend
enhanc
neutral
result
mirror
sera
gener
construct
often
incap
neutral
even
highli
sensit
isol
intend
immun
hyperglycosyl
mutant
effect
dampen
elicit
weakli
neutral
antibodi
similar
unfortun
succeed
elicit
like
antibodi
combin
lower
level
crown
direct
antibodi
may
potenti
explain
disappear
neutral
activ
type
sera
concept
dampen
immun
respons
unwant
area
hyperglycosyl
continu
use
hyperglycosyl
trimer
construct
trimer
hyperglycosyl
construct
use
heterolog
trimer
domain
result
significantli
reduc
avail
loop
measur
monoclon
antibodi
bind
reflect
immun
sera
result
protein
base
immun
construct
neutral
sensit
isol
dramat
reduc
result
fewer
antibodi
elicit
variabl
loop
viru
context
dampen
immun
respons
unwant
area
strategi
succeed
howev
within
context
focus
antibodi
respons
desir
area
bind
site
strategi
still
need
undergo
develop
hyperglycosyl
envelop
dampen
immun
respons
particular
region
one
strategi
involv
manipul
glycosyl
site
envelop
protein
anoth
strategi
involv
elimin
particular
glycosyl
site
order
enhanc
immunogen
envelop
one
attempt
elimin
n
link
glycosyl
site
first
second
variabl
loop
infecti
siv
isol
glycosyl
mutant
isol
use
infect
rhesu
monkey
result
humor
respons
compar
elicit
infect
parent
wild
type
viru
rel
humor
respons
rais
wild
type
viru
mutant
glycosyl
viru
demonstr
shift
specif
degycosyl
region
loop
well
increas
neutral
activ
sera
second
studi
determin
elimin
singl
n
link
glycan
stem
loop
background
could
dramat
effect
phenotyp
antigen
immunogen
model
immunogen
immun
macaqu
vaccinia
vector
encod
glycan
delet
construct
follow
boost
recombin
protein
dramat
increas
potenc
neutral
homolog
mutant
parent
viru
well
increas
breadth
neutral
panel
heterolog
clade
b
deriv
primari
isol
howev
whether
result
hold
true
envelop
specif
background
remain
seen
number
studi
attempt
similar
mutat
studi
elimin
n
link
glycosyl
site
howev
shown
mutant
better
immunogen
parent
viru
nativ
envelop
spike
hiv
viru
structur
consist
three
subunit
possibl
effect
immunogen
may
need
mimic
trimer
structur
order
elicit
effect
neutral
antibodi
respons
creation
trimer
mimic
proven
difficult
task
howev
owe
mostli
fact
interact
surfac
virion
govern
weak
noncoval
interact
limit
make
product
evalu
trimer
immunogen
difficult
task
number
strategi
employ
attempt
overcom
hurdl
one
strategi
employ
elimin
cleavag
site
would
normal
result
process
precursor
matur
compon
modif
construct
elimin
transmembran
intracellular
tail
result
rel
stabl
trimer
construct
use
immunogen
studi
one
studi
use
strategi
immun
rabbit
monomer
trimer
construct
deriv
iiib
envelop
ribi
mplse
adjuv
result
antibodi
respons
capabl
bind
construct
homolog
heterolog
isol
increas
potenc
neutral
antibodi
respons
anim
immun
trimer
construct
also
observ
tcla
virus
mn
serum
test
prototyp
primari
isol
howev
neutral
activ
observ
despit
trimer
construct
also
test
macaqu
result
sera
capabl
neutral
tcla
strain
hiv
epitop
map
analysi
sera
reveal
usual
high
neutral
activ
could
adsorb
use
peptid
predomin
direct
antibodi
limit
exposur
loop
primari
isol
could
potenti
explain
littl
neutral
primari
isol
observ
studi
also
use
strategi
elimin
cleavag
site
attempt
increas
yield
oligm
produc
one
compar
immunogen
monomer
oligomer
deriv
independ
isol
four
protein
base
immun
power
adjuv
antibodi
respons
test
neutral
activ
larg
panel
primari
isol
clade
b
c
group
three
rabbit
least
two
three
rabbit
receiv
base
immun
capabl
neutral
one
viral
isol
test
comparison
two
three
rabbit
receiv
monomer
base
immunogen
capabl
neutral
nine
forti
six
isol
test
second
mean
use
stabil
trimer
interact
studi
immunogen
addit
heterolog
trimer
domain
hiv
envelop
one
exampl
introduc
foldon
trimer
domain
background
immun
trimer
construct
initi
shown
effect
rais
potent
neutral
antibodi
respons
mice
vaccin
trimer
construct
use
wide
varieti
adjuv
guinea
pig
gener
increas
potenc
neutral
select
homolog
heterolog
clade
b
isol
howev
littl
expand
breadth
neutral
isol
compar
immun
monomer
analysi
neutral
activ
reveal
immun
anim
neutral
activ
direct
primarili
toward
loop
viru
addit
neutral
activ
direct
toward
loop
interestingli
immun
construct
redirect
neutral
activ
away
loop
area
viru
trimer
construct
also
gener
use
motif
test
rabbit
gener
pattern
increas
potenc
neutral
activ
sera
observ
studi
interestingli
studi
also
look
effect
stabil
bound
state
trimer
form
site
direct
mutagenesi
addit
modif
stabil
core
trimer
form
increas
potenc
elicit
neutral
antibodi
respons
even
howev
overal
breadth
neutral
increas
appreci
difficult
neutral
isol
jrfl
also
interest
note
specif
neutral
activ
differ
two
studi
guinea
pig
immun
trimer
structur
neutral
activ
could
attribut
recognit
rabbit
immun
similar
construct
almost
neutral
activ
could
attribut
reactiv
attempt
induc
trimer
envelop
also
success
made
instead
introduct
heterolog
trimer
motif
stabil
normal
envelop
trimer
enhanc
introduct
disulfid
bond
stabil
interact
mutat
region
made
stabil
interact
modif
allow
trimer
cleav
normal
still
maintain
stabl
trimer
interact
studi
evalu
immunogen
disulfid
bond
stabil
construct
high
titer
bind
antibodi
weak
neutral
activ
observ
specif
homolog
jrfl
isol
immunogen
gener
neutral
sporad
upon
immun
construct
neutral
tcla
isol
mn
also
evalu
studi
sera
gener
immun
construct
frequent
neutral
viru
high
titer
howev
trend
higher
neutral
antibodi
titer
rais
anim
immun
trimer
second
studi
also
evalu
effect
trimer
immun
rabbit
trimer
construct
result
delet
cleavag
site
trimer
construct
base
intermolecular
disulfid
bond
immun
monomer
studi
littl
improv
function
antibodi
respons
elicit
trimer
protein
sporad
neutral
homolog
isol
jrfl
seen
trimer
immun
anim
well
sporad
neutral
sensit
isol
bal
howev
almost
neutral
resist
primari
isol
observ
analysi
neutral
sera
studi
indic
neutral
activ
direct
toward
loop
viru
mper
region
limit
amount
neutral
activ
could
assign
loop
well
leav
exact
specif
neutral
activ
observ
larg
undefin
seri
neutraliz
epitop
found
membran
proxim
extern
region
mper
howev
region
shown
poorli
immunogen
effort
increas
immunogen
region
linear
epitop
mper
region
recogn
broadli
neutral
antibodi
specif
graft
area
envelop
one
studi
transplant
epitop
either
loop
test
dna
base
immun
mice
graft
construct
gener
posit
bind
antibodi
mper
epitop
place
either
loop
howev
immun
guinea
pig
fail
rais
posit
antibodi
titer
intact
mper
posit
loop
interestingli
repeat
immun
mper
graft
loop
rais
posit
antibodi
respons
target
graft
epitop
guinea
pig
despit
posit
recognit
epitop
howev
mper
base
neutral
observ
viru
iiib
immunogen
mper
epitop
graft
loop
also
assess
mice
rabbit
graft
region
manipul
addit
delet
residu
flank
epitop
order
manipul
exposur
helix
graft
proven
capabl
bind
mper
direct
antibodi
immunogen
rabbit
assess
mani
bind
antibodi
gener
studi
neutral
antibodi
target
mper
region
detect
yet
anoth
interest
approach
focus
gener
effect
antibodi
respons
use
antiidiotyp
antibodi
immunogen
focu
antibodi
respons
desir
domain
antiidiotyp
antibodi
capabl
bind
bind
site
direct
fraction
human
sera
hiv
infect
individu
also
evalu
immunogen
studi
enrich
fraction
bind
site
direct
antibodi
four
long
term
non
progressor
use
fraction
gener
antiidiotyp
monoclon
antibodi
mice
two
monoclon
gener
capabl
bind
subsequ
use
fab
form
adjuv
ifa
immunogen
rabbit
best
two
fab
immunogen
capabl
neutral
sensit
isol
three
five
rabbit
howev
data
neutral
activ
sera
repres
primari
isol
given
ultim
goal
rais
strong
antibodi
respons
prevent
hiv
infect
design
effect
antigen
use
vaccin
one
part
overal
effort
gener
protect
antibodi
respons
second
equal
import
task
optim
deliveri
method
optim
env
antigen
administ
human
success
antibodi
respons
rais
pursu
goal
number
differ
strategi
implement
tabl
use
tradit
subunit
protein
vaccin
attempt
first
detail
discuss
howev
sheer
difficulti
rais
effect
antibodi
respons
viru
necessit
use
novel
immun
approach
one
novel
approach
use
viral
vector
deliv
antigen
one
applic
approach
evalu
phase
human
trial
use
adenoviru
vector
deliv
env
antigen
studi
use
adenoviru
deliveri
system
made
replic
incompet
delet
region
well
part
region
viral
genom
insert
viru
gene
encod
gagpol
fusion
protein
intend
elicit
cell
respons
well
three
envelop
gene
deriv
singl
clade
clade
b
clade
c
isol
four
week
immun
individu
capabl
recogn
homolog
clade
b
antigen
ipwestern
blot
antibodi
respons
measur
elisa
howev
individu
capabl
recogn
one
three
antigen
use
vaccin
formul
despit
posit
bind
titer
induc
individu
neutral
activ
detect
highli
sensit
isol
tcla
isol
therefor
vaccin
prove
rel
safe
fail
gener
highli
immunogen
humor
respons
even
sensit
virus
use
canarypox
viru
deliv
hiv
antigen
also
evalu
phase
ii
human
trial
uninfect
individu
immun
canarypox
vector
encod
protein
mn
fuse
region
hiv
isol
lai
plu
entir
gag
gene
ctl
epitop
deriv
nef
pol
protein
canarypox
immun
either
administ
alon
boost
subunit
protein
boost
bival
formul
deriv
isol
mn
total
four
immun
posit
bind
antibodi
rais
gag
protein
percent
individu
depend
immun
group
relevantli
howev
individu
rais
neutral
antibodi
respons
homolog
isol
mn
notabl
individu
receiv
canarypox
base
immun
elicit
lower
titer
neutral
antibodi
mn
neutral
heterolog
isol
iiib
also
evalu
limit
number
sampl
heterolog
neutral
taken
account
individu
receiv
canarypox
base
immun
fare
significantli
wors
receiv
subunit
protein
booster
specif
individu
assay
receiv
canarypox
immun
never
success
neutral
iiib
individu
receiv
subunit
protein
boost
abl
neutral
viru
case
gener
antibodi
respons
capabl
neutral
tcla
strain
viru
use
similar
canarypox
primeprotein
boost
immun
regimen
also
mirror
number
studi
demonstr
util
heterolog
primeboost
regimen
despit
abil
overal
qualiti
antibodi
respons
trial
appear
better
report
trial
conduct
strictli
subunit
protein
base
immun
notabl
abil
individu
neutral
signific
number
neutral
resist
primari
isol
yet
demonstr
trial
sole
use
dna
base
immun
rais
specif
antibodi
respons
also
test
human
trial
one
trial
three
dna
immun
encod
three
envelop
antigen
one
deriv
clade
b
c
well
cell
antigen
gag
pol
nef
given
healthi
human
volunt
use
needl
free
inject
system
antibodi
respons
trial
evalu
elisa
neutral
antibodi
assay
humor
respons
recogn
clade
c
envelop
gener
individu
clade
b
recogn
individu
trial
despit
presenc
bind
antibodi
function
neutral
antibodi
entir
lack
none
vaccin
individu
gener
neutral
antibodi
sensit
isol
mn
indic
overal
lack
immunogen
approach
gener
strong
antibodi
respons
result
mirror
second
human
dna
vaccin
trial
trial
deliv
dna
encod
gagpolnef
fusion
protein
plu
modifi
envelop
construct
deriv
clade
b
c
via
needl
free
inject
system
similar
dna
trial
bind
antibodi
determin
elisa
rais
individu
howev
total
lack
neutral
antibodi
respons
rais
sensit
strain
mn
third
trial
util
dna
base
immun
encod
gag
pol
env
rev
tat
vpu
deliv
tradit
needl
base
intramuscular
inject
also
fail
produc
detect
nab
titer
isol
ada
mn
sole
use
dna
base
immun
human
highlight
fact
whole
dna
vaccin
immunogen
howev
puzzl
immun
sera
neutral
even
highli
sensit
isol
posit
bind
antibodi
respons
clearli
identifi
one
possibl
explan
use
modifi
env
antigen
dna
vaccin
alon
studi
multipl
delet
domain
result
construct
remain
cell
associ
combin
mutat
may
advers
affect
critic
envelop
conform
requir
elicit
neutral
antibodi
respons
base
upon
limit
abil
vaccin
util
singl
modal
rais
effect
antibodi
respons
combin
heterolog
immun
approach
also
attempt
one
studi
use
dna
prime
adenoviru
boost
elicit
cellular
humor
immun
rhesu
macaqu
studi
use
dna
virus
express
three
hiv
envelop
clade
b
c
either
alon
combin
well
fuse
gagpolnef
construct
intend
rais
cell
mediat
immun
studi
gener
strong
cell
mediat
immun
respons
viru
function
antibodi
respons
still
somewhat
lack
posit
bind
antibodi
titer
rais
immun
anim
well
posit
neutral
sensit
isol
inhibit
three
clade
isol
observ
anim
receiv
combin
three
envelop
immunogen
howev
inhibit
major
primari
isol
clade
b
c
entir
lack
despit
low
level
neutral
antibodi
respons
immun
demonstr
posit
effect
challeng
immun
anim
demonstr
better
control
viral
infect
well
better
preserv
cell
compart
studi
evalu
elicit
antibodi
respons
use
combin
dna
adenovirus
also
perform
studi
immun
rhesu
macaqu
chimer
construct
deliv
either
dna
primeadenoviru
boost
strictli
repeat
immun
rad
evalu
immun
singl
vector
gener
higher
bind
titer
protein
compar
immun
dna
vaccin
howev
repeat
boost
immun
anim
addit
viru
enhanc
antibodi
respons
contrast
dna
prime
anim
administ
boost
demonstr
rapid
rise
envelop
bind
titer
neutral
activ
rais
two
immun
approach
also
evalu
neutral
isol
found
significantli
greater
anim
first
receiv
dna
prime
indic
superior
combin
immun
approach
rel
immun
howev
breadth
neutral
use
dna
prime
boost
format
still
somewhat
limit
third
test
clade
b
isol
neutral
sera
gener
immun
either
chimer
construct
use
dna
vaccin
rais
humor
respons
first
seen
earli
nineti
shown
dna
plasmid
encod
env
deriv
tcla
capabl
rais
specif
antibodi
respons
small
anim
antibodi
rais
approach
capabl
bind
recombin
env
protein
well
neutral
isol
iiib
util
approach
demonstr
shiv
challeng
model
cynolomog
macaqu
studi
anim
receiv
dna
immun
gener
strong
immun
respons
result
lower
viral
load
compar
unimmun
anim
addit
studi
one
four
immun
anim
protect
viral
challeng
upon
complet
dna
immun
regimen
obviou
abil
gener
immun
respons
number
posit
aspect
dna
immun
make
attract
option
use
platform
vaccin
first
endogen
product
process
chosen
antigen
dna
immun
given
antigen
encod
plasmid
taken
directli
cell
inject
site
host
therebi
make
antigen
product
similar
live
attenu
vaccin
allow
protein
undergo
well
regul
translat
process
allow
nativ
fold
well
normal
post
translat
modif
glycosyl
antigen
interest
addit
endogen
product
antigen
produc
protein
effici
present
immun
system
class
class
ii
mhc
complex
allow
effici
cell
respons
antigen
furthermor
dna
vaccin
also
proven
safe
altern
subunit
live
attenu
vaccin
dna
vaccin
normal
nonrepl
non
integr
encod
protein
interest
dna
vaccin
allow
research
elicit
antibodi
respons
specif
subunit
vaccin
nativ
antigen
process
live
attenu
vaccin
without
safeti
risk
revers
attenu
viral
strain
pathogen
one
addit
rel
safeti
dna
base
immun
provid
excel
platform
studi
differ
properti
particular
antigen
screen
differ
immunogen
identifi
immunogen
neutral
domain
target
well
identifi
effect
immun
regimen
despit
dna
vaccin
abil
gener
immun
respons
model
antigen
number
caveat
still
exist
includ
rel
low
vivo
transfect
effici
lead
low
level
antigen
product
signific
effort
appli
order
increas
potenc
dna
vaccin
includ
studi
differ
deliveri
mechan
dna
method
includ
electropor
needl
free
jet
system
gene
gun
microneedl
inject
intend
increas
effici
dna
deliveri
tradit
intramuscular
inject
increas
effici
dna
deliveri
one
aspect
effort
increas
potenc
dna
immun
work
also
focus
design
dna
construct
order
enhanc
antigen
product
level
individu
transfect
cell
one
primari
improv
made
advent
implement
codon
optim
maxim
effici
trna
usag
cell
optim
codon
util
preval
trna
present
cell
allow
effici
protein
translat
result
higher
quantiti
antigen
produc
work
increas
amount
antigen
produc
focus
manipul
leader
sequenc
promot
construct
simultan
manipul
factor
potenti
construct
shown
improv
immunogen
protein
mous
model
despit
improv
design
dna
construct
increas
effici
deliveri
dna
immun
still
capabl
produc
limit
quantiti
antigen
level
much
lower
deliv
inactiv
subunit
vaccin
wit
dna
vaccin
alon
human
trial
immunogen
enough
gener
effect
antibodi
respons
viru
despit
dna
immun
highli
effect
prime
bodi
immun
system
work
best
use
combin
anoth
immun
approach
usual
dna
administ
prime
immun
follow
boost
modal
one
simplest
effect
combin
approach
elicit
humor
immun
dna
prime
follow
tradit
subunit
protein
boost
earli
studi
use
dna
primeprotein
boost
approach
util
tcla
deriv
env
protein
vaccin
formul
rabbit
studi
immun
dna
base
immun
encod
replic
incompet
form
subsequ
boost
deriv
isol
iiib
incomplet
freund
adjuv
ifa
limit
bind
antibodi
gener
dna
immun
boost
recombin
protein
greatli
increas
bind
titer
immun
anim
analysi
serum
avid
elicit
immun
regimen
indic
use
combin
approach
elicit
higher
avid
antibodi
respons
use
dna
immun
alon
combin
dna
primeprotein
boost
approach
gener
homolog
neutral
antibodi
titer
significantli
greater
observ
immun
anim
recombin
protein
heterolog
neutral
antibodi
respons
mn
also
gener
use
prime
boost
immun
regimen
titer
immun
anim
vari
exceed
mn
howev
agreement
later
studi
use
tcla
deriv
immunogen
shown
incap
gener
heterolog
neutral
antibodi
respons
difficult
neutral
primari
isol
extens
ground
work
done
demonstr
dna
primeprotein
boost
strategi
effect
mean
rais
antibodi
respons
small
anim
nonhuman
primat
howev
mani
studi
suffer
inabl
neutral
relev
primari
isol
one
breakthrough
attempt
overcom
limit
tcla
deriv
immunogen
use
deriv
primari
isol
jrfl
model
immunogen
studi
rabbit
immun
either
dna
primeprotein
boost
format
recombin
protein
deriv
primari
isol
jrfl
sera
gener
immun
approach
contain
high
level
bind
antibodi
homolog
envelop
neutral
antibodi
respons
gener
immun
regimen
differ
dramat
one
exampl
observ
neutral
sensit
isol
immun
regimen
capabl
gener
neutral
antibodi
respons
sensit
isol
howev
dna
prime
anim
much
higher
titer
addit
anim
receiv
dna
prime
capabl
neutral
homolog
strain
jrfl
pbmc
base
neutral
assay
inhibit
neutral
resist
primari
isol
observ
anim
immun
protein
addit
sera
rais
dna
primeprotein
boost
approach
also
frequent
capabl
neutral
heterolog
clade
b
isol
includ
superior
dna
primeprotein
boost
approach
proven
concurr
separ
studi
look
effect
oligomer
state
elicit
neutral
antibodi
use
dna
primeprotein
boost
approach
elicit
fold
higher
bind
antibodi
respons
compar
immun
protein
clearli
demonstr
potenti
platform
elicit
function
antibodi
respons
viru
third
exampl
effect
dna
primeprotein
boost
vaccin
approach
use
monomer
immunogen
gener
consist
nab
respons
neutral
resist
primari
isol
use
dna
primeprotein
boost
approach
abl
enhanc
bind
neutral
antibodi
respons
elicit
compar
immun
subunit
protein
overal
breadth
neutral
activ
still
somewhat
limit
like
explan
phenomenon
use
singl
subtyp
b
envelop
vaccin
formul
one
attempt
made
increas
breadth
neutral
activ
includ
multipl
genet
distinct
envelop
singl
polyval
formul
studi
rabbit
immun
dna
primeprotein
boost
format
consist
either
monoval
polyval
formul
deriv
clade
b
c
e
f
g
sera
gener
immun
construct
test
pseudoviru
base
neutral
assay
panel
virus
clade
ae
data
studi
reveal
immun
polyval
formul
significantli
increas
breadth
neutral
multiclad
panel
nearli
doubl
number
isol
neutral
compar
monoval
immun
group
success
dna
primeprotein
boost
immun
format
show
promis
non
human
primat
studi
extent
modif
polyval
formul
consist
two
clade
b
one
clade
c
one
clade
e
plu
gag
deriv
test
protect
efficaci
rhesu
macaqu
anim
receiv
combin
dna
protein
base
immun
subsequ
rectal
challeng
shiv
bal
time
challeng
anim
gener
antibodi
respons
capabl
neutral
sensit
isol
hiv
mn
well
challeng
strain
bal
immun
regimen
provid
steril
immun
four
six
macaqu
shiv
challeng
base
upon
detect
viral
rna
blood
rel
control
group
seven
anim
becam
infect
demonstr
high
viral
load
remain
two
immun
macaqu
becam
infect
demonstr
lower
level
viral
rna
blood
gag
antigen
isol
viru
receiv
shiv
challeng
protect
clearli
mediat
envinduc
immun
like
due
antienv
antibodi
studi
also
confirm
util
dna
primeprotein
boost
approach
nonhuman
primat
one
studi
use
primeboost
approach
neonat
macaqu
immun
anim
studi
dna
encod
vpu
iiib
envelop
follow
boost
recombin
iiib
deriv
protect
anim
homolog
iiib
intraven
shiv
challeng
anoth
studi
util
dna
primeprotein
boost
approach
immun
rhesu
macaqu
form
envelop
deriv
homolog
neutral
antibodi
titer
exceed
gener
result
immun
construct
follow
intraven
challeng
shiv
none
immun
monkey
becam
infect
base
upon
neg
reisol
everi
bleed
challeng
base
success
protect
nonhuman
primat
shiv
protect
model
dna
primeprotein
boost
approach
test
phase
clinic
trial
polyval
envelop
formul
use
time
consist
five
envelop
clade
b
c
e
three
dna
immun
two
protein
boost
humor
respons
evalu
solid
phase
antibodi
bind
neutral
antibodi
assay
immun
polyval
env
vaccin
formul
regimen
elicit
broad
high
titer
bind
antibodi
respons
individu
enrol
trial
antigen
clade
h
evalu
elisa
western
blot
addit
neutral
antibodi
respons
detect
individu
sensit
isol
mn
titer
high
neutral
homolog
primari
isol
includ
vaccin
also
frequent
observ
specif
neutral
activ
detect
individu
subtyp
c
vaccin
strain
addit
elicit
neutral
antibodi
sensit
homolog
isol
alway
demonstr
trial
new
polyval
dna
primeprotein
boost
regimen
also
gener
neutral
activ
difficult
neutral
heterolog
primari
isol
clade
b
c
e
high
throughput
pseudotyp
viru
base
neutral
system
posit
nab
titer
identifi
vaccine
includ
analysi
vaccine
posit
nab
pseudotyp
virus
includ
assay
repres
signific
improv
neutral
antibodi
respons
report
immun
via
protein
dna
viral
vector
alon
well
combin
viral
vector
primeprotein
boost
dna
primevir
vector
boost
studi
addit
vaccin
success
gener
cross
reactiv
antibodi
respons
also
prove
safe
well
toler
underli
mechan
dna
primeprotein
boost
immun
regimen
effect
rais
function
antibodi
respons
still
fulli
understood
one
potenti
explan
avid
antibodi
respons
gener
hiv
envelop
primeboost
immun
higher
gener
immun
either
modal
alon
studi
indic
boost
recombin
protein
vastli
increas
avid
antibodi
respons
elicit
dna
prime
gener
higher
avid
antibodi
respons
may
one
defin
featur
necessari
elicit
effect
neutral
second
possibl
dna
primeprotein
boost
approach
elicit
higher
qualiti
antibodi
respons
also
recent
investig
comparison
antibodi
specif
gener
immun
recombin
protein
dna
primeprotein
boost
approach
reveal
incorpor
dna
prime
alter
specif
elicit
antibodi
base
upon
enhanc
breadth
neutral
antibodi
respons
observ
dna
prime
anim
specif
antibodi
elicit
immun
approach
studi
recognit
linear
peptid
deriv
group
consensu
sequenc
reveal
immun
either
approach
gener
bind
antibodi
region
envelop
howev
immun
dna
primeprotein
boost
approach
also
elicit
antibodi
specif
flank
region
loop
region
junction
region
map
region
onto
crystal
structur
ligand
reveal
uniqu
recogn
region
map
close
known
contact
residu
use
monoclon
antibodi
competit
assay
confirm
increas
titer
bind
site
direct
antibodi
present
anim
receiv
dna
prime
interestingli
howev
direct
antibodi
also
observ
elicit
higher
titer
dna
prime
anim
investig
phenomenon
reveal
direct
antibodi
preval
dna
prime
anim
play
signific
role
neutral
primari
isol
left
increas
level
bind
site
antibodi
like
mechan
observ
enhanc
neutral
antibodi
respons
recent
studi
implic
bind
site
primari
target
individu
broadli
neutral
activ
abil
dna
primeprotein
boost
approach
elicit
antibodi
specif
remark
import
attribut
platform
develop
effect
vaccin
still
face
numer
challeng
may
becom
realiti
includ
enhanc
antibodi
respons
neutral
wide
array
viral
isol
high
degre
potenc
howev
current
work
underway
use
polyval
env
formul
deliv
dna
primeprotein
boost
approach
elicit
broadli
cross
reactiv
antibodi
respons
challeng
may
prove
insurmount
make
neutraliz
epitop
immunogen
present
differ
context
increas
nab
specif
graft
biodrug
author
manuscript
avail
pmc
septemb
low
titer
broad
nab
respons
wide
rang
primari
isol
